Eurestobart

尤瑞苏拜单抗

Report date: 2024/02/04 17:57:58

Base Information

Drug NameEurestobart
Drug Alias NameES-002023
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Ectonucleoside triphosphate diphosphohydrolase 1
TargetsEctonucleoside triphosphate diphosphohydrolase 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesElpiscience (Shanghai) Biopharma Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesElpiscience Biopharma LtdElpiscience (Suzhou) Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A